Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study

Journal of Digestive Diseases

Volumn 14, Issue 4, 2013, Pages 181-190

  Bai, Wei ^a   Wang, Yong Ji ^b   Zhao, Yan ^a   Qi, Xing Shun ^a   Yin, Zhan Xin ^a   He, Chuang Ye ^a   Li, Rui Jun ^a   Wu, Kai Chun ^a   Xia, Jie Lai ^b   Fan, Dai Ming ^a   Han, Guo Hong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Sorafenib; Survival; Transarterial chemoembolization

Indexed keywords

DOXORUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; SORAFENIB;

ADULT; ALOPECIA; ARTICLE; BARCELONA CLINIC LIVER CANCER STAGE; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; SCORING SYSTEM; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPENSITY SCORE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84875609144     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12038     Document Type: Article

References (34)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
3. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005; 5: 131-138.
4. Lo CM, Ngan H, Tso WK etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
5. Llovet JM, Real MI, Montaña X etal. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442.
7. Takayasu K, Arii S, Ikai I etal. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469.
8. Takayasu K, Arii S, Ikai I etal. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010; 194: 830-837.
9. Luo J, Guo RP, Lai EC etal. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18: 413-420.
10. Chung GE, Lee JH, Kim HY etal. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634.
11. Forner A, Trinchet JC. Transarterial therapies in HCC: does embolization increase survival? J Hepatol 2009; 51: 981-983.
12. Sergio A, Cristofori C, Cardin R etal. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921.
13. Mathonnet M, Descottes B, Valleix D, Labrousse F, Truffinet V, Denizot Y. Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 3782-3783.
14. Llovet JM, Ricci S, Mazzaferro V etal; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
15. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
16. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003; 3: 19.
17. Yoshida T, Hisamoto T, Akiba J etal. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 2006; 25: 6056-6066.
18. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007; 14: 1835-1845.
19. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007; 6: 1932-1941.
20. Wada H, Nagano H, Yamamoto H etal. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1α. Liver Int 2006; 26: 414-423.
21. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenteriology 2011; 140: 1410-1426.
22. Strebel BM, Dufour JF. Combined approach to hepatollular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008; 8: 1743-1749.
23. Kudo M, Imanaka K, Chida N etal. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-2127.
24. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
25. Therasse P, Arbuck SG, Eisenhauer EA etal; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
26. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008; 27: 2037-2049.
27. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
28. Siegel AB, Olsen SK, Magun A, Brown RS Jr. Sorafenib: where do we go from here? Hepatology 2010; 52: 360-369.
29. Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010; 17: 120-129.
30. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004; 11: 1077-1084.
31. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
32. A phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolization (TACE) performed with DC bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC). [Updated 29 October 2012; cited 26 January 2013]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00855218?term=sorafenib+TACE&rank=10
33. Chao Y, Yoon J, Li C etal. START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. 2010 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, USA.
34. Yau T, Chan P, Ng KK etal. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-436.